Abcam Plc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Abcam Plc (ABCM) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Abcam Plc vs Its Competitors
- TTM: Trailing 12-month revenue of 447M vs 275M combined for tracked competitors (62.0% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+300.0% annualized vs trailing 12 months), vs accelerating (+29.3%) for its tracked peer group.
- Profitability: Its -2.4% net margin compares with -14.8% for the peer group.
- Peer revenue share: Abcam Plc accounted for 83.4% of combined revenue among its tracked peer group.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
ABCM Sales vs. its Competitors, Q4 2022
With a net margin of -2.35 %, Abcam Plc achieved higher profitability than its competitors (-14.76 %).
Abcam Plc generated 83.44 % of the combined sales of its peer group.
Abcam Plc vs. its Competitors, Q4 2022
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Abcam Plc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Abcam Plc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (1) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Abcam Plc's competitor groups requires a Commercial License.
Abcam Plc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Abcam Plc | - | - | - | - |
| Competitors combined (3) | ||||
| High-Confidence Competitors (1) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
ABCM Stock Performance relative to its Competitors
ABCM Stock Performance relative to High-Confidence Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Immunoprecise Antibodies Ltd | 282.9% | Outperformed |
| 2 | Cryoport inc | 282.9% | Outperformed |
| 3 | Harvard Bioscience Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Abcam Plc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Publicly Traded Peers of Abcam Plc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Abcam Plc | 5,548.89 | 447.47 |
| Cryoport inc | 877.70 | 186.45 |
| Immunoprecise Antibodies Ltd | 69.11 | 17.60 |
| Harvard Bioscience Inc | 35.85 | 88.16 |
| SUBTOTAL | 6,531.55 | 739.68 |
Sources: Abcam Plc's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Abcam Plc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Abcam Plc's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Bio techne Corp | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Abcam Plc's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Abcam Plc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Cryoport inc | Life Sciences Services 58.40 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Abcam Plc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Abcam Plc | 5,549 | - | - |
| Cryoport inc | 878 | 252,645 | -53,790 |
| Immunoprecise Antibodies Ltd | 69 | 13,773 | -16,982 |
| Harvard Bioscience Inc | 36 | 260,071 | -30,714 |
| PEERS TOTAL | 983 | 124,084 | -30,494 |
Abcam Plc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Cryoport inc | Americas 73.14 % |
| Harvard Bioscience Inc | US 43.49 % |
Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Abcam Plc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Latest-quarter revenue run-rate is accelerating (+300.0% annualized vs trailing 12 months).
Weaknesses
No rule matched.
Opportunities
- Industry revenue growing at a healthy 10.0% median pace.
- A meaningful share of tracked competitors (33.30 %) show financial-distress signals, a possible opening to gain share.
Threats
No rule matched.
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Abcam Plc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Abcam Plc | 0.44 | 1.27 | - |
| Cryoport inc | 2.02 | 2.73 | 0.28 |
| Immunoprecise Antibodies Ltd | 1.20 | 2.08 | - |
| Harvard Bioscience Inc | 0.23 | 1.49 | 3.15 |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Abcam Plc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Abcam Plc | Q4 2022 | +3.1 % | - |
| Cryoport inc | Q2 2026 | +7.7 % | - |
| Immunoprecise Antibodies Ltd | Q1 2025 | -3.1 % | - |
| Harvard Bioscience Inc | Q2 2026 | +16.4 % | - |
| PEERS TOTAL | +3.8 % | - |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Abcam Plc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Abcam Plc | Q4 2022 | -9.7 % | -56.2 % |
| Cryoport inc | Q2 2026 | +8.6 % | +58.2 % |
| Immunoprecise Antibodies Ltd | Q1 2025 | -14.7 % | -44.6 % |
| Harvard Bioscience Inc | Q2 2026 | +26.2 % | +293.1 % |
Abcam Plc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Abcam Plc | - | - | - |
| Cryoport inc | - | - | - |
| Immunoprecise Antibodies Ltd | - | - | - |
| Harvard Bioscience Inc | - | - | - |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Abcam Plc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Abcam Plc | - | 12.40 |
| Cryoport inc | - | 4.71 |
| Immunoprecise Antibodies Ltd | - | 3.93 |
| Harvard Bioscience Inc | - | 0.41 |
| PEERS AVERAGE | - | 8.83 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.